Search - tctmd.com

Displaying 181 - 200 of 752

Sort: Relevancy | Date

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

News Daily News

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

July 06, 2018

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

June 25, 2018

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

News Daily News

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

June 12, 2018

TCTMD’s Top 10 Most Popular Stories for May 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2018

June 01, 2018

Thrombus on the Watchman LAA Occluder Tied to Higher Stroke Risk

News Conference News HRS 2018

Thrombus on the Watchman LAA Occluder Tied to Higher Stroke Risk

May 14, 2018

NOACs Perform Worse Than Warfarin in Real-World Study, Especially When Adherence Is Low

News Conference News HRS 2018

NOACs Perform Worse Than Warfarin in Real-World Study, Especially When Adherence Is Low

May 11, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

‘Practical Guide’ for NOACs Gets an Update

News Daily News

‘Practical Guide’ for NOACs Gets an Update

March 20, 2018

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

News Conference News ACC 2018

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

March 15, 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

News Conference News ACC 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

March 12, 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

News Daily News

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

Michael O'Riordan

February 12, 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

News Conference News ISC 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

January 30, 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

News Conference News ISC 2018

More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs

January 27, 2018

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

January 02, 2018

Surgical Aortic Valve Repair Effective, Durable in Experienced Hands

News Daily News

Surgical Aortic Valve Repair Effective, Durable in Experienced Hands

December 21, 2017

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

News Daily News

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Yael L. Maxwell

November 28, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.